I
Intrinsic Therapeutics | Formerly MedGenesis Inc
Manufacturer of Barricaid Annular Closure. Designed to prevent reherniation
About Intrinsic Therapeutics | Formerly MedGenesis Inc
Intrinsic Therapeutics, Inc. is a medical device company established in 2000, operating from Woburn, Massachusetts. The company's inception is credited to Greg Lambrecht, who was inspired to find a better solution for recurrent disc herniations after witnessing his mother's experience with the condition. Lambrecht, an inventor with a background in Mechanical and Nuclear Engineering from MIT, also founded other medical device companies, including Coravin and Viacor, and held significant roles at Stryker and Pfizer's Medical Technology Group.
The company's core business revolves around the development and commercialization of the Barricaid® Annular Closure Device, a spinal implant designed to address a significant unmet need in spinal surgery. The Barricaid is intended for patients undergoing lumbar discectomy, a common procedure to treat herniated discs. It aims to reduce the high rate of reherniation and subsequent reoperations by closing the defect left in the outer wall of the disc (the annulus fibrosus) after surgery. The target clients are primarily surgeons and healthcare professionals who perform these spinal procedures. Revenue is generated through the sale of the Barricaid device, which is marketed through distributors in Europe, Australia, Mexico, the Middle East, and other regions, as well as in the United States.
The Barricaid device is a permanent implant with two main components: a titanium bone anchor that secures the device to an adjacent vertebral body and a flexible polymer barrier designed to block the hole in the annulus. This design is engineered to withstand the pressure within the spinal disc while allowing for normal anatomical movement post-surgery. The device received FDA Pre-Market Approval (PMA) in 2019, a significant milestone that followed a rigorous, multi-center, randomized superiority trial involving 554 patients. This study demonstrated that Barricaid was superior to the standard discectomy procedure alone in reducing reherniation and reoperation rates. As of June 2025, the device has been implanted in over 12,000 patients and was used for the first time in an endoscopic approach. The company has secured substantial funding to support its operations, including a $49 million round in 2017 and a $52 million round in 2019, with investors like New Enterprise Associates (NEA), Questa Capital, and Delos Capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 91
- Open positions
- None listed
- Dealroom signal
- 77.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology, Medical Devices
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Apr 2023 | $5.9M | $260M | Undisclosed | ↗ |
| SERIES EOther financing | Apr 2019 | $52M | $208M | NEA · Greenspring Associates · Delos Capital · Quadrille Capital | — |
Growth signals
Latest recorded traffic for Intrinsic Therapeutics | Formerly MedGenesis Inc is 0 monthly website visits. Intrinsic Therapeutics | Formerly MedGenesis Inc's team grew 5.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Intrinsic Therapeutics | Formerly MedGenesis Inc in the Woburn ecosystem
The Intrinsic Therapeutics | Formerly MedGenesis Inc office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later4 investors entered at this stage
Greenspring Associates
Delos Capital
Quadrille Capital
Questa Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Intrinsic Therapeutics | Formerly MedGenesis Inc on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Intrinsic Therapeutics | Formerly MedGenesis Inc’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











